Age-Related Macular Degeneration

A 70-year-old man presented for an urgent visit to the retina clinic for sudden painless vision loss of his right eye.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, shares an update on Duravyu for wet age-related macular degeneration.

A 32-year-old woman was referred by the rheumatology service for a second opinion regarding high-risk medication use evaluation.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, of Cleveland Clinic Florida discusses the need for anti-VEGF biosimilars and the possibility of on-label bevacizumab.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.

BARCELONA, Spain – In this Healio Video Perspective from the Euretina congress, David Wong, MD, shares his thoughts on the advantages of new drugs for retinal conditions including age-related macular degeneration.

BARCELONA, Spain – In this Healio Video Perspective at the Euretina congress, Baruch D. Kuppermann, MD, PhD, delivers an overview of new compounds currently under investigation for dry age-related macular degeneration.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Michael W. Stewart, MD, shares his experience with Eylea HD in neovascular age-related macular degeneration and diabetic macular edema.

The FDA granted investigational drug clearance to HG202, a CRISPR/Cas13Y RNA-editing therapy for neovascular age-related macular degeneration, according to a press release from HuidaGene.